Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

LocoMMotion MajesTEC-1 MoMMent Relapsed or refractory multiple myeloma Teclistamab Triple-class exposed

Journal

Advances in therapy

ISSN: 1865-8652

Titre abrégé: Adv Ther

Pays: United States

ID NLM: 8611864

Informations de publication

Date de publication:
19 Dec 2023

Historique:

received: 06 10 2023

accepted: 14 11 2023

medline: 19 12 2023

pubmed: 19 12 2023

entrez: 19 12 2023

Statut: aheadofprint

Résumé

Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared the effectiveness of teclistamab in MajesTEC-1 versus real-world physician's choice of therapy (RWPC) in patients from the prospective, non-interventional LocoMMotion and MoMMent studies. Patients treated with teclistamab from MajesTEC-1 (N = 165) were compared with an external control arm from LocoMMotion (N = 248) or LocoMMotion + MoMMent pooled (N = 302). Inverse probability of treatment weighting adjusted for imbalances in prognostic baseline characteristics. The relative effect of teclistamab versus RWPC for overall response rate (ORR), very good partial response or better (≥ VGPR) rate, and complete response or better (≥ CR) rate was estimated with an odds ratio using weighted logistic regression transformed into a response-rate ratio (RR) and 95% confidence interval (CI). Weighted proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Baseline characteristics were well balanced between treatment cohorts after reweighting. Patients treated with teclistamab had significantly improved outcomes versus RWPC in LocoMMotion: ORR (RR [95% CI], 2.44 [1.79-3.33]; p < 0.0001), ≥ VGPR (RR 5.78 [3.74-8.93]; p < 0.0001), ≥ CR (RR 113.73 [15.68-825.13]; p < 0.0001), DOR (HR 0.39 [0.24-0.64]; p = 0.0002), PFS (HR 0.48 [0.35-0.64]; p < 0.0001), and OS (HR 0.64 [0.46-0.88]; p = 0.0055). Teclistamab versus RWPC in LocoMMotion + MoMMent also had significantly improved outcomes: ORR (RR 2.41 [1.80-3.23]; p < 0.0001), ≥ VGPR (RR 5.91 [3.93-8.88]; p < 0.0001), ≥ CR (RR 132.32 [19.06-918.47]; p < 0.0001), DOR (HR 0.43 [0.26-0.71]; p = 0.0011), PFS (HR 0.49 [0.37-0.66]; p < 0.0001), and OS (HR 0.69 [0.50-0.95]; p = 0.0247). Teclistamab demonstrated significantly improved effectiveness over RWPC in LocoMMotion ± MoMMent, emphasizing its clinical benefit as a highly effective treatment for patients with TCE RRMM. MajesTEC-1, ClinicalTrials.gov NCT03145181 (phase 1) and NCT04557098 (phase 2); LocoMMotion, ClinicalTrials.gov NCT04035226; MoMMent, ClinicalTrials.gov NCT05160584.

Identifiants

DOI: 10.1007/s12325-023-02738-0 PMID: 38110653

pubmed: 38110653

doi: 10.1007/s12325-023-02738-0

pii: 10.1007/s12325-023-02738-0

doi:

Banques de données

ClinicalTrials.gov

['NCT05160584', 'NCT04557098', 'NCT04035226', 'NCT03145181']

Types de publication

Journal Article

Langues

eng

Informations de copyright

Références

Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102(1):1–11. https://doi.org/10.1007/s00277-022-05058-5 .

doi: 10.1007/s00277-022-05058-5 pubmed: 36462062

Franssen LE, Mutis T, Lokhorst HM, van de Donk N. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660. https://doi.org/10.1177/2040620718822660 .

doi: 10.1177/2040620718822660 pubmed: 30719268 pmcid: 6348514

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528. https://doi.org/10.1097/hs9.0000000000000528 .

doi: 10.1097/hs9.0000000000000528 pubmed: 33554050 pmcid: 7861652

Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):26. https://doi.org/10.1038/s41408-018-0065-8 .

doi: 10.1038/s41408-018-0065-8 pubmed: 29531285 pmcid: 5849889

Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49:100808. https://doi.org/10.1016/j.blre.2021.100808 .

doi: 10.1016/j.blre.2021.100808 pubmed: 33863601

Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087. https://doi.org/10.1186/s12885-020-07503-y .

doi: 10.1186/s12885-020-07503-y pubmed: 33172403 pmcid: 7656738

Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–6. https://doi.org/10.1038/s41375-022-01531-2 .

doi: 10.1038/s41375-022-01531-2 pubmed: 35332278 pmcid: 9061296

Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–75. https://doi.org/10.1038/s41375-019-0435-7 .

doi: 10.1038/s41375-019-0435-7 pubmed: 30858549 pmcid: 6820050

ABECMA (idecabtagene vicleucel). Package insert. Bristol-Myers Squibb Company; 2021.

ABECMA (idecabtagene vicleucel). Summary of product characteristics. Celgene Distribution BV; 2021.

CARVYKTI (ciltacabtagene autoleucel). Janssen Biologics BV; 2022.

CARVYKTI (ciltacabtagene autoleucel). Package insert. Janssen Biotech, Inc.; 2022.

Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265–74. https://doi.org/10.1200/jco.22.00842 .

doi: 10.1200/jco.22.00842 pubmed: 35658469

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. https://doi.org/10.1056/NEJMoa2024850 .

doi: 10.1056/NEJMoa2024850 pubmed: 33626253

Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. https://doi.org/10.1056/NEJMoa2203478 .

doi: 10.1056/NEJMoa2203478 pubmed: 35661166 pmcid: 10587778

Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–44. https://doi.org/10.1056/NEJMoa2204591 .

doi: 10.1056/NEJMoa2204591 pubmed: 36507686

Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–67. https://doi.org/10.1038/s41591-023-02528-9 .

doi: 10.1038/s41591-023-02528-9 pubmed: 37582952 pmcid: 10504075

TECVAYLI (teclistamab-cqyv). Package insert. Janssen Biotech, Inc; 2022.

TECVAYLI (teclistamab). Summary of product characteristics. Janssen Biologics BV; 2022.

ELREXFIO (elranatamab-bcmm). Package insert. Pfizer, Inc; 2023.

TALVEY (talquetamab-tgvs). Package insert. Janssen Biotech, Inc; 2023.

TALVEY (talquetamab). Summary of product characteristics. Janssen Biologics BV; 2023.

NEXPOVIO (selinexor). Summary of product characteristics. Stemline Therapeutics BV; 2021.

XPOVIO (selinexor). Package insert. Karyopharm Therapeutics; 2019.

Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–38. https://doi.org/10.1056/NEJMoa1903455 .

doi: 10.1056/NEJMoa1903455 pubmed: 31433920

van de Donk NWCJ. Long-term follow-up from MajesTEC-1 of teclistamab, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL, USA & Virtual.

Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective locommotion study in patients with triple-class-exposed relapsed and/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412–25. https://doi.org/10.1007/s12325-023-02480-7 .

doi: 10.1007/s12325-023-02480-7 pubmed: 36961654 pmcid: 10129954

Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486–94. https://doi.org/10.1002/ajh.25963 .

doi: 10.1002/ajh.25963 pubmed: 32804408 pmcid: 7754114

Mateos MV. Comparative effectiveness of teclistamab vs real-world physician’s choice of therapy in the locomotion and moment studies for patients with triple-class exposed relapsed/refractory multiple myeloma. In: Presented at the 20th International Myeloma Society (IMS) Annual Meeting; September 27–30, 2023; Athens, Greece.

Weisel K. Standard of care outcomes in the last 3 years in patients with triple-class exposed relapsed/refractory multiple myeloma: the first pooled analysis of LocoMMotion and MoMMent Trials. The 20th International Myeloma Society (IMS) Annual Meeting; September 27–30, 2023; Athens, Greece.

Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/s1470-2045(16)30206-6 .

doi: 10.1016/s1470-2045(16)30206-6 pubmed: 27511158

Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390–400. https://doi.org/10.1080/01621459.2016.1260466 .

doi: 10.1080/01621459.2016.1260466

Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107. https://doi.org/10.1002/sim.3697 .

doi: 10.1002/sim.3697 pubmed: 19757444 pmcid: 3472075

Moreau P. LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma—final analysis at 2-year follow-up. In: Presented at the European Hematology Association (EHA) 2023 Hybrid Congress; June 8–11, 2023; Frankfurt, Germany.

Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–28. https://doi.org/10.1016/j.jval.2011.04.002 .

doi: 10.1016/j.jval.2011.04.002 pubmed: 21669366

Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200–11. https://doi.org/10.1177/0272989x17725740 .

doi: 10.1177/0272989x17725740

Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S13–S21. https://doi.org/10.1002/ajh.26628 .

doi: 10.1002/ajh.26628 pubmed: 35702871

Myeloma UK Selinexor Horizons Infosheet. https://www.myeloma.org.uk/library/selinexor-infosheet/ . Accessed Aug 7, 2023.

BLENREP (belantamab mafodotin-blmf). Summary of product characteristics. GlaxoSmithKline Manufacturing SpA; 2020.

GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. 2022. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation . Accessed Sept 20, 2023.

EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023. https://www.ema.europa.eu/en/news/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep . Accessed Sept 19, 2023.

Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transplant Cell Ther. 2023;29(4):255–8. https://doi.org/10.1016/j.jtct.2023.01.012 .

doi: 10.1016/j.jtct.2023.01.012 pubmed: 36681151